Published in Br J Cancer on May 04, 2004
Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer (2008) 3.98
CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol (2006) 2.34
Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J Biol (2008) 1.71
Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer (2008) 1.53
Role of nuclear factor κB-mediated inflammatory pathways in cancer-related symptoms and their regulation by nutritional agents. Exp Biol Med (Maywood) (2011) 1.18
Is neurodegenerative disease a long-latency response to early-life genotoxin exposure? Int J Environ Res Public Health (2011) 1.14
Evaluating the dimensionality of perceived cognitive function. J Pain Symptom Manage (2009) 1.08
The association between pro-inflammatory cytokines, regional cerebral metabolism, and cognitive complaints following adjuvant chemotherapy for breast cancer. Brain Imaging Behav (2013) 0.95
Chemobrain: a translational challenge for neurotoxicology. Neurotoxicology (2008) 0.89
Risk of subsequent dementia diagnoses does not vary by types of adjuvant chemotherapy in older women with breast cancer. Med Oncol (2008) 0.84
Fluoxetine counteracts the cognitive and cellular effects of 5-fluorouracil in the rat hippocampus by a mechanism of prevention rather than recovery. PLoS One (2012) 0.84
Broadening the cancer and cognition landscape: the role of self-regulatory challenges. Psychooncology (2013) 0.81
Psychological intervention for improving cognitive function in cancer survivors: a literature review and randomized controlled trial. Front Oncol (2015) 0.80
Metallothionein induction reduces caspase-3 activity and TNFalpha levels with preservation of cognitive function and intact hippocampal neurons in carmustine-treated rats. Oxid Med Cell Longev (2010) 0.80
Neuropsychological testing and biomarkers in the management of brain metastases. Radiat Oncol (2008) 0.79
Evaluation of multiple neurotoxic outcomes in cancer chemotherapy. Adv Exp Med Biol (2010) 0.77
Chemotherapy-related changes in cognitive functioning. EJC Suppl (2013) 0.77
Why, After Chemotherapy, is it Necessary to Assess Memory Using Translational Testing? Breast Cancer (Auckl) (2012) 0.76
Cognitive effects of donepezil therapy in patients with brain tumors: a pilot study. J Neurooncol (2016) 0.75
Impaired Brain Dopamine and Serotonin Release and Uptake in Wistar Rats Following Treatment with Carboplatin. ACS Chem Neurosci (2016) 0.75
Global and regional brain glucose metabolism decline after systemic chemotherapy. Eur J Nucl Med Mol Imaging (2015) 0.75
Brain structure and function in patients with ovarian cancer treated with first-line chemotherapy: a pilot study. Brain Imaging Behav (2016) 0.75
Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med (2001) 4.39
Estrogen actions in the central nervous system. Endocr Rev (1999) 3.64
Cytokine-induced sickness behavior. Brain Behav Immun (2003) 2.70
Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol (1994) 2.59
Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst (2003) 2.48
Modulation of cognition-specific cortical activity by gonadal steroids: a positron-emission tomography study in women. Proc Natl Acad Sci U S A (1997) 2.19
Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int (2002) 2.18
Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA (1998) 2.14
Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc (2003) 2.00
Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life. Ann Neurol (2003) 2.00
The role of cytokines in cancer-related fatigue. Cancer (2001) 1.75
Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neuro Oncol (2003) 1.74
Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol (2000) 1.66
Neurological complications of radiotherapy and chemotherapy. J Neurol (1998) 1.56
Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat (2000) 1.40
Factors affecting risk of symptomatic temporal lobe necrosis: significance of fractional dose and treatment time. Int J Radiat Oncol Biol Phys (2002) 1.39
Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology (Berl) (2000) 1.35
Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology (2001) 1.34
Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol (2000) 1.32
Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery (2000) 1.20
Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-alpha treatments in cancer patients. Psychosom Med (2001) 1.20
Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol (1998) 1.16
A longitudinal neuropsychological study of partial brain radiation in adults with brain tumors. Neurology (2003) 1.15
Neurocognitive effects of therapeutic irradiation for base of skull tumors. Int J Radiat Oncol Biol Phys (2000) 1.14
Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. J Neurooncol (2001) 1.06
Radiation therapy of brain tumors. Cancer (1977) 1.04
Androgen deprivation and cognition in prostate cancer. Br J Cancer (2003) 1.04
The predictive value of longitudinal neuropsychologic assessment in the early detection of brain tumor recurrence. Cancer (2003) 1.03
Cognitive deficits in patients with small cell lung cancer before and after chemotherapy. Lung Cancer (1995) 1.03
Neuropsychologic dysfunction in women following leuprolide acetate induction of hypoestrogenism. J Assist Reprod Genet (1993) 0.96
Neuropsychometric evaluation of long-term survivors of adult brain tumours: relationship with tumour and treatment parameters. Radiother Oncol (1996) 0.93
A prospective study of cognitive functions following conventional radiotherapy for supratentorial gliomas in young adults: 4-year results. Int J Radiat Oncol Biol Phys (1996) 0.89
Effects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy. Clin Breast Cancer (2002) 0.87
Neurotoxicity of CI-980, a novel mitotic inhibitor. Clin Cancer Res (1997) 0.87
Cognitive performance and magnetic resonance imaging findings after high-dose systemic and intraventricular chemotherapy for primary central nervous system lymphoma. Arch Neurol (2003) 0.86
Cognitive functioning in cancer patients: effect of previous treatment. Neurology (1992) 0.84
An assessment of agonist/antagonist effects of tamoxifen in the female mouse brain. Horm Behav (1992) 0.81
Reversible neurotoxicity of interleukin-2 and tumor necrosis factor: correlation of SPECT with neuropsychological testing. J Neuropsychiatry Clin Neurosci (1994) 0.77
The effect of anti-oestrogens on cytokine production in vitro. Scand J Immunol (1996) 0.76
Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem (1983) 9.32
Purification and initial characterization of a type beta transforming growth factor from human placenta. Proc Natl Acad Sci U S A (1983) 3.52
Purification and properties of a type beta transforming growth factor from bovine kidney. Biochemistry (1983) 3.49
Synergistic interaction of two classes of transforming growth factors from murine sarcoma cells. Cancer Res (1982) 2.70
Synthetic peptides corresponding to keratin subunits elicit highly specific antibodies. J Biol Chem (1984) 1.96
Cognitive functioning and quality of life in malignant glioma patients: a review of the literature. Psychooncology (1997) 1.87
A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry (2002) 1.73
Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurology (1995) 1.71
Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas. Int J Radiat Oncol Biol Phys (2002) 1.61
Hypothalamic regulatory hormones. Annu Rev Biochem (1978) 1.60
Klüver-Bucy syndrome after bilateral selective damage of amygdala and its cortical connections. J Neuropsychiatry Clin Neurosci (1998) 1.59
Recombinant HIV-1 reverse transcriptase: purification, primary structure, and polymerase/ribonuclease H activities. Arch Biochem Biophys (1989) 1.41
Vav cooperates with Ras to transform rodent fibroblasts but is not a Ras GDP/GTP exchange factor. Oncogene (1994) 1.30
Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol (1998) 1.16
Purification and characterization of human recombinant interleukin-1 beta. J Biol Chem (1987) 1.16
Postoperative mutism in neurosurgery. Report of two cases. J Neurosurg (1994) 1.13
Synthesis and biological actions of prosomatostatin. Proc Natl Acad Sci U S A (1980) 1.07
Relationship between quality of life and mood in long-term survivors of breast cancer treated with mastectomy. Support Care Cancer (1997) 1.07
Highly active position eight analogues of somatostatin and separation of peptide diastereomers by partition chromatography. Biochemistry (1978) 1.07
A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor. J Neurooncol (2011) 1.05
Orientation of peptide fragments from Sos proteins bound to the N-terminal SH3 domain of Grb2 determined by NMR spectroscopy. Biochemistry (1994) 1.02
Treatment of neurotoxic side effects of interferon-alpha with naltrexone. Cancer Invest (1995) 0.98
Solution structure of the Grb2 N-terminal SH3 domain complexed with a ten-residue peptide derived from SOS: direct refinement against NOEs, J-couplings and 1H and 13C chemical shifts. J Mol Biol (1997) 0.98
A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin Cancer Res (1997) 0.98
Psychosocial functioning and quality of life in patients with primary brain tumors. J Neurosurg (1996) 0.94
Ventricular enlargement after closed head injury. Arch Neurol (1981) 0.94
Cognitive dysfunction following surgery for intracerebral glioma: influence of histopathology, lesion location, and treatment. J Neurooncol (1996) 0.93
Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. Int J Radiat Oncol Biol Phys (1995) 0.92
Developing a care giver quality-of-life instrument. Preliminary steps. Cancer Pract (1997) 0.92
Cognitive and mood disturbance as causes and symptoms of fatigue in cancer patients. Cancer (2001) 0.90
Secretion of N-glycosylated interleukin-1 beta in Saccharomyces cerevisiae using a leader peptide from Candida albicans. Effect of N-linked glycosylation on biological activity. J Biol Chem (1991) 0.90
Potent, highly selective inhibition of growth hormone secretion by position 4 somatostatin analogs. Endocrinology (1981) 0.90
Methylphenidate in the treatment of neurobehavioral slowing associated with cancer and cancer treatment. J Neuropsychiatry Clin Neurosci (1995) 0.89
A retrospective study of the psychiatric management and outcome of delirium in the cancer patient. Support Care Cancer (1996) 0.89
The hippocampus: normal anatomy and pathology. AJR Am J Roentgenol (1998) 0.88
NGF gene transfer to intrinsic basal forebrain neurons increases cholinergic cell size and protects from age-related, spatial memory deficits in middle-aged rats. Brain Res (2000) 0.88
Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma. Anticancer Drugs (1998) 0.86
Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity. J Med Chem (1996) 0.86
Prophylactic treatment of depression induced by interferon-alpha. Psychosomatics (2000) 0.86
Structure-activity studies with somatostatin: the role of tryptophan in position 8. Regul Pept (1980) 0.85
Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: inclusion of quality of life and other patient-reported outcomes. Crit Rev Oncol Hematol (2011) 0.85
Efficacy of postacute brain injury rehabilitation for patients with primary malignant brain tumors. Cancer (1997) 0.84
Mutism after closed head injury. Arch Neurol (1983) 0.84
Transforming growth factors from a human tumor cell: characterization of transforming growth factor beta and identification of high molecular weight transforming growth factor alpha. Biochemistry (1985) 0.83
The multisubunit IkappaB kinase complex shows random sequential kinetics and is activated by the C-terminal domain of IkappaB alpha. J Biol Chem (1998) 0.82
Linguistic recovery after closed head injury. Brain Lang (1981) 0.82
Early versus late lateral ventricular enlargement following closed head injury. J Neurol Neurosurg Psychiatry (1983) 0.82
[Phe4]somatostatin: a potent, selective inhibitor of growth hormone release. Proc Natl Acad Sci U S A (1980) 0.81
Activity of VIP, somatostatin and other peptides in the mouse vas deferens assay. Pharmacol Biochem Behav (1978) 0.81
Selective inhibition of glucagon and insulin secretion by somatostatin analogs. Proc Soc Exp Biol Med (1979) 0.80
Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer. Cancer Chemother Pharmacol (2000) 0.80
Gastrointestinal secretory, motor, circulatory, and metabolic effects of prosomatostatin. Proc Natl Acad Sci U S A (1981) 0.79
Somatostatin, basic and clinical studies. A review. Mater Med Pol (1982) 0.79
Medical problems encountered during rehabilitation of patients with head injury. Arch Phys Med Rehabil (1985) 0.78
Human pancreatic polypeptide inhibits insulin release in the rat. Biochem Biophys Res Commun (1981) 0.78
Selective effect of some somatostatin analogs on glucagon as opposed to insulin release in rats in vivo. Metabolism (1980) 0.78
Effects of prosomatostatin on growth hormone and prolactin response to arginine in man. Comparison with somatostatin. Lancet (1981) 0.78
Effect of human pancreatic polypeptide and its C-terminal hexapeptide on pancreatic secretion in man and in the dog. Scand J Gastroenterol (1982) 0.78
Manic episodes in two patients treated with interferon alpha. J Neuropsychiatry Clin Neurosci (1997) 0.77
Micelle-bound conformational preferences of a peptide derived from a murine major histocompatibility complex class I molecule. J Biol Chem (1993) 0.77
Secretion of interleukin-1 beta and Escherichia coli galactokinase by Streptomyces lividans. J Bacteriol (1988) 0.77
Immunocytochemical localization of CRF in the ovine hypothalamus. Peptides (1982) 0.77
Peptides corresponding to the N and C termini of IkappaB-alpha, -beta, and -epsilon as probes of the two catalytic subunits of IkappaB kinase, IKK-1 and IKK-2. J Biol Chem (1999) 0.76
Use of the mouse vas deferens assay to evaluate the action of somatostatin peptides on gastric acid secretion. Digestion (1981) 0.76
Impairment of remote memory after closed head injury. J Neurol Neurosurg Psychiatry (1985) 0.76
Successful treatment of interferon-alpha-induced mood disorder with nortriptyline. Psychosomatics (1995) 0.76
Differentiation of somatostatin receptors involved in inhibition of gastric acid and growth hormone secretion with halogenated Trp8 analogues [proceedings]. J Physiol (1978) 0.75
St. Ansgar Hospital, Moorhead, MN. Volunteer-staffed center supervises visitors', outpatients' children. Hosp Prog (1981) 0.75
Inhibition of growth hormone and glucagon release by Phe-4-somatostatin in patients with acromegaly. Res Commun Chem Pathol Pharmacol (1984) 0.75
Introduction to hippocampal spectroscopy. Neuroimaging Clin N Am (1997) 0.75
Sensitive radioimmunoassay for somatostatin using N-[125I]-Tyr-somatostatin as labelled antigen. Clin Endocrinol (Oxf) (1979) 0.75
Suppression of somatostatin levels in the hepatic portal and systemic plasma of the rat by synthetic human pancreatic polypeptide. Biochem Biophys Res Commun (1979) 0.75
Quality of life and neurobehavioural functioning in patients with malignant gliomas. Baillieres Clin Neurol (1996) 0.75
Selective inhibition of sleep related growth hormone release by Phe-4-somatostatin. Res Commun Chem Pathol Pharmacol (1984) 0.75
The opioid mechanism of interferon-alpha action. Anticancer Drugs (1994) 0.75
Solid-phase synthesis of human pancreatic polypeptide. Int J Pept Protein Res (1980) 0.75
A pseudopeptide incorporating the tetrahydrophthalazine nucleus, a constrained aza analog of phenylalanine. Int J Pept Protein Res (1996) 0.75
Neurochemical basis of interleukin 2-modified discrimination behaviour. Cytokine (1994) 0.75